Dr Xavier Hadoux is Head of the Ophthalmic Neuroscience Unit at the Centre for Eye Research Australia (CERA) and the co-founder and Chief Executive Officer (CEO) of Enlighten Imaging Pty Ltd.

Dr Hadoux completed his PhD in data science at Montpellier University, France, in 2014. He also holds a Master of Science and a Master of Engineering from the Grande École in Nancy, France. Since moving to Australia in 2015, he has applied his background in engineering, physics and data science to medical imaging – with a particular focus on developing non-invasive technologies for detecting early biomarkers of eye and brain diseases.

Dr Hadoux leads the development of a world-first hyperspectral retinal imaging platform, combining proprietary imaging hardware with AI-based analytics. His research has contributed to key discoveries in retinal biomarkers for Alzheimer’s disease, age-related macular degeneration (AMD), diabetic retinopathy and ocular tumours. He is first author of the landmark study that reported the first in-vivo retinal biomarker for Alzheimer’s disease, and lead inventor on multiple patents for hyperspectral imaging and analysis.

He has published over 30 peer-reviewed papers and is currently leading the development of a regulatory-grade hyperspectral camera and AI foundation model trained on one of the largest spectral retinal datasets in the world. This work is supported by competitive commercialisation funding and is progressing toward TGA and FDA submission.

Dr Hadoux also co-developed XMAS: an open-source cross-modality annotation tool used to accelerate the creation of high-quality training datasets for ophthalmic AI research.